Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Ependymoma × Cytarabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 174 Leukemia 95 Lymphoma 77 Precursor Cell Lymphoblastic Leukemia-Lymphoma 72 Burkitt Lymphoma 45 Myelodysplastic Syndromes 43 Lymphoma, Mantle-Cell 41 Lymphoma, Large B-Cell, Diffuse 40 Lymphoma, Non-Hodgkin 39 Leukemia, Monocytic, Acute 28 Leukemia, Myelomonocytic, Acute 27 Lymphoma, Follicular 26 Leukemia, Erythroblastic, Acute 23 Recurrence 22 Lymphoma, Large-Cell, Immunoblastic 22 Leukemia, Megakaryoblastic, Acute 22 Congenital Abnormalities 21 Hodgkin Disease 18 Leukemia, Lymphocytic, Chronic, B-Cell 17 Leukemia, Myelomonocytic, Chronic 16 Blast Crisis 15 Anemia, Refractory, with Excess of Blasts 14 Lymphoma, B-Cell, Marginal Zone 13 Myeloproliferative Disorders 11 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11 Dendritic Cell Sarcoma, Interdigitating 11 Multiple Myeloma 10 Leukemia, Myeloid, Chronic-Phase 10 Leukemia, Myeloid, Accelerated Phase 10 Leukemia, Biphenotypic, Acute 10

Interventions

Magnetic Resonance Spectroscopy 9 Bevacizumab 9 Temozolomide 7 Etoposide 7 Cyclophosphamide 7 X-Rays 6 Phantoms, Imaging 6 Specimen Handling 5 Nuclear Medicine Department, Hospital 5 Irinotecan 4 Filgrastim 4 Cisplatin 4 Biopsy 4 Radiotherapy 3 Erlotinib Hydrochloride 3 Carboplatin 3 ulixertinib 2 tipifarnib 2 tazemetostat 2 selpercatinib 2 sargramostim 2 palbociclib 2 olaparib 2 larotrectinib 2 ivosidenib 2 etoposide phosphate 2 erdafitinib 2 ensartinib 2 Vincristine 2 Vemurafenib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01356290 2026-02-23

MEMMAT

Medical University of Vienna

Phase 2 Recruiting

Ependymoma, Medulloblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡